EUCTR2014-003590-41-DE进行中（未招募）不适用
Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for inclusion in this trial must fulfill all of the following criteria:
- •1. Acute cough with symptoms lasting 2-3 days prior to treatment
- •2. Men or women of any ethnic origin
- •3. Age 18 to 75 years
- •4. Subjects who are able to understand and are willing to comply to trial instructions
- •5. Having given written informed consent
- •6. Satisfactory health except for the cough as determined by the investigator based on medical history and physical examination
- •7. CS score of at least 50 mm on a 100 mm VAS at V1
- •8. Acute BSS of at least 10 points at V1
- •9. VCD score of at least 2 points at V1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Subjects eligible for inclusion in this trial must not fulfill any of the following criteria:
- •1. Allergic bronchial asthma, bronchial hyperreactivity, chronic bronchitis, other chronic or inherited lung disease
- •2. History of hypersensitivity to any excipient of the applied drugs
- •3. History of drug hypersensitivity, asthma, urticaria, or other severe allergic diathesis as well as current hay fever
- •4. History of chronic gastritis or peptic ulcers
- •5. Any gastrointestinal complaints within 7 days before V1
- •6. Participation in a clinical trial within 30 days prior to the treatment phase of this study or concomitantly
- •7. Treatment with corticoids, beta-2 agonists (e.g. salbutamol, fenoterol), expectorants, theophylline, antitussives, anaesthetics, acetylsalicylic acid (e.g. aspirin) or other non-steroidal anti-inflammatory drugs, leukotriene inhibitors, angiotensin-converting enzyme (ACE) inhibitors, antiviral drugs or antibiotics, antihistamines, immunosuppressants, isoprenaline, atropine, sodium cromoglycate or homeopathic drugs against common cold within 7 days before V1
- •8. Drug or alcohol abuse in the opinion of the investigator
- •9. Pregnant or nursing (lactating) women
- •10. Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) who are not using an acceptable method of contraception defined as:
- •Surgical sterilization
- •Hormonal contraception
- •Intra-Uterine Device (IUD)
- •Double barrier method
- •Total abstinence throughout the trial at the discretion of the investigator
- •Periodic abstinence is NOT an acceptable method of contraception. An acceptable method of contraception must be maintained throughout the trial.
- •A woman who is post-menopausal must have a negative urine pregnancy test at screening but will not need to comply with an acceptable method of contraception. Women are considered post-menopausal and not of child-bearing potential if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- •11. Subjects with significant diseases, defined as a disease which, in the opinion of the investigator, may either put the subject at risk because of participation in the trial or a disease which may influence the results of the trial or the subject’s ability to participate in the trial; includes subjects with a history of gastrointestinal bleeding, significant cardiovascular, liver or renal disease.
- •12. Subjects directly or indirectly involved in the execution of this protocol, including employees of the CRO and persons related to them.
研究者
相似试验
进行中（未招募）
1 期
ocal symptomatic and short-term treatment of pain in acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuriesAcute blunt, soft tissue injuries of the limbsMedDRA version: 20.0Level: LLTClassification code 10041775Term: Sprains and strains of ankle and footSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10032894Term: Other specified sites of sprains and strainsSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041777Term: Sprains and strains of elbow and forearmSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041790Term: Sprains and strains of shoulder and upper armSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10041798Term: Sprains and strains of wrist and handSystem Organ Class: 100000004863MedDRA version: 21.0Level: LLTClassification code 10019428Term: HematomaSystem Organ Class: 100000004866EUCTR2019-001038-32-DEead Chemical Company Ltd132
进行中（未招募）
1 期
A study to evaluate efficacy and safety of an Esflurbiprofen Hydrogel Patch vs. placebo in the local symptomatic and short-term treatment of pain in acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuriesAcute strains, sprains or bruises of the extremities following blunt traumaMedDRA version: 20.0Level: LLTClassification code 10002549Term: Ankle sprainSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10002550Term: Ankle sprains and strainsSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10028338Term: Muscle sprainsSystem Organ Class: 100000004863MedDRA version: 20.0Level: LLTClassification code 10028361Term: Muscular painSystem Organ Class: 100000004859MedDRA version: 21.1Level: LLTClassification code 10028362Term: Muscular painsSystem Organ Class: 100000004859MedDRA version: 20.1Level: LLTClassification code 10006502Term: BruiseSystem Organ Class: 100000004863EUCTR2020-005165-14-DETeikoku Seiyaku Co Ltd.200
尚未招募
1 期
Randomized, controlled, double-blind, multicenter, prospective clinical study and mechanism exploration of Qinggan Sanjie Xiaoying Decoction in treating Hashimoto's thyroiditisHashimoto's thyroiditisITMCTR2200006524Sun Simiao Hospital of Beijing University of traditional Chinese Medicine
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)EUCTR2013-000768-27-GRBayer HealthCare AG7,000
进行中（未招募）
1 期
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 18.1 Level: PT Classification code 10014498 Term: Embolic stroke System Organ Class: 10029205 - Nervous system disordersEUCTR2013-000768-27-PTBayer HealthCare AG7,213